Introduction
tumors
METASTATIC COLORECTAL CANCER, TUMORS
Monoclonal antibodies targeting epidermal growth factor receptors (EGFRs) have led to significant improvements in survival for patients with metastatic colorectal cancer (mCRC).Studies of acquired resistance to EGFRi show that progressing tumors remain dependent on extracellular signal-regulated kinase (ERK) activation but that resistance alterations bypass EGFR inhibition to maintain ERK signaling.Binimetinib (MEK162) is a selective, potent allosteric inhibitor of MEK1/2 that has demonstrated antitumor activity in preclinical models.This trial evaluates the combination of binimetinib and the EGFR inhibitor panitumumab in patients with 